e.g. mhealth
Search Results (1 to 10 of 34 Results)
Download search results: CSV END BibTex RIS
Skip search results from other journals and go to results- 10 Journal of Medical Internet Research
- 8 JMIR Formative Research
- 5 JMIR Public Health and Surveillance
- 4 JMIR Research Protocols
- 2 JMIR Infodemiology
- 2 JMIR mHealth and uHealth
- 1 JMIR Cancer
- 1 JMIR Medical Informatics
- 1 JMIR Pediatrics and Parenting
- 0 Medicine 2.0
- 0 Interactive Journal of Medical Research
- 0 iProceedings
- 0 JMIR Human Factors
- 0 JMIR Serious Games
- 0 JMIR Mental Health
- 0 JMIR Rehabilitation and Assistive Technologies
- 0 JMIR Preprints
- 0 JMIR Bioinformatics and Biotechnology
- 0 JMIR Medical Education
- 0 JMIR Challenges
- 0 JMIR Diabetes
- 0 JMIR Biomedical Engineering
- 0 JMIR Data
- 0 JMIR Cardio
- 0 Journal of Participatory Medicine
- 0 JMIR Dermatology
- 0 JMIR Aging
- 0 JMIR Perioperative Medicine
- 0 JMIR Nursing
- 0 JMIRx Med
- 0 JMIRx Bio
- 0 Transfer Hub (manuscript eXchange)
- 0 JMIR AI
- 0 JMIR Neurotechnology
- 0 Asian/Pacific Island Nursing Journal
- 0 Online Journal of Public Health Informatics
- 0 JMIR XR and Spatial Computing (JMXR)
HPV vaccination is the single most important primary preventive measure for HPV [7-9]. A systematic review of HPV vaccine programs across 69 countries over ten years found estimated maximal reductions of 90% for HPV 6/11/16/18 strain infection (ie, the most common cancer-causing strains), 90% for genital warts, and 45% for low-grade and 85% for high-grade cytological cervical abnormalities [10]. HPV also plays an important role in anal, vulvar, penile, and oropharyngeal cancer [4].
JMIR Mhealth Uhealth 2025;13:e63527
Download Citation: END BibTex RIS
We provide a case study, focusing on the development of human papillomavirus (HPV) vaccine messages for parents who use Twitter (rebranded as X in 2023), a microblogging social media platform, to share evidence and findings to support the development of future online CAB creation. Briefly, the HPV vaccine is an important topic for child and adolescent health, and parents are critical stakeholders in deciding whether their child receives the HPV vaccine.
JMIR Form Res 2025;9:e65986
Download Citation: END BibTex RIS
While proactive recommendations were reinstated in 2022, HPV vaccine uptake remains low [14-18].
To enhance HPV vaccination uptake in Japan, it is crucial to systematically analyze the trends of vaccine hesitancy. Existing literature reveals varying levels of hesitancy across different populations.
J Med Internet Res 2025;27:e68881
Download Citation: END BibTex RIS
Over the last few decades, the incidence of invasive cervical cancer in the United States has decreased due to the high uptake of preventive screening and access to human papillomavirus (HPV) vaccination [1-3]. However, there are large and persistent disparities in cervical cancer incidence [4,5] and mortality [6] among minoritized populations [7-11].
JMIR Form Res 2025;9:e55043
Download Citation: END BibTex RIS
Given the young age of the HPV vaccine target population, this study will focus on HPV vaccine hesitancy among the parents of girls aged 9-14 years. A recent study in mainland China reported that 53.9% of the guardians of secondary school girls aged 12-19 years were HPV vaccine hesitant, mainly because of a lack of knowledge of HPV vaccines and insufficient communication from reliable sources of information [19].
JMIR Res Protoc 2024;13:e58873
Download Citation: END BibTex RIS
Electronic Health Interventions and Cervical Cancer Screening: Systematic Review and Meta-Analysis
The primary methods for cervical cancer screening include Papanicolaou smears, HPV DNA testing, cytological examinations, and colposcopy. The WHO advocates HPV DNA testing as the preferred initial screening approach, regardless of whether a triage strategy is used. Women who test positive in the HPV DNA test are recommended to undergo further evaluation through genotyping, colposcopy, visual inspection with acetic acid, or cytological examination [6].
J Med Internet Res 2024;26:e58066
Download Citation: END BibTex RIS
Human papillomavirus (HPV) is one of the most commonly transmitted sexual infections [1]. There are over 200 types of HPV, some of which cause cancer (eg, cervical, oropharyngeal, and genital) or genital warts (ie, condylomas) [1]. Most of the oncogenic HPV types can be prevented by vaccination [1]. In Quebec, Canada, HPV vaccination has been offered as part of school-based vaccination programs to boys and girls in grade 4 since 2008.
JMIR Form Res 2024;8:e57118
Download Citation: END BibTex RIS
Almost all cases are attributable to human papillomavirus (HPV), for which an effective vaccine exists [1]. Part of the global strategy to eliminate cervical cancer includes fully vaccinating 90% of girls with the HPV vaccine by the age of 15 years [2]. However, the global HPV immunization coverage currently remains suboptimal [3].
JMIR Infodemiology 2024;4:e50551
Download Citation: END BibTex RIS
The incidence rate ratios of cytology-based screening, HPV-based screening, and HPV vaccination were based on the studies of Chen et al [30], Ronco et al [24], and Lei et al [5]. We assume that HPV vaccination administered to 13-year-old girls affords them lifetime effectiveness against cervical cancer [31]. HPV-based screening may have a higher false positive rate, so it is suggested that screening be performed once every 5-10 years [24].
JMIR Public Health Surveill 2024;10:e46360
Download Citation: END BibTex RIS
The breadth and depth of COVID-19 misinformation expanded to include all vaccinations, such as human papillomavirus (HPV) vaccination, depressing already suboptimal vaccination uptake in the United States [1,2]. As HPV vaccination is critical to the prevention of various cancers, this could pose significant cancer control challenges in the future [2]. There is an urgent need to address HPV vaccination misinformation to increase HPV vaccination uptake [2].
JMIR Infodemiology 2024;4:e54000
Download Citation: END BibTex RIS